This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: D66 | Special Copayment Reduction: V009 (rare disease, 10% copayment for 5 years after registration) |
| B. Synonyms | Hemophilia A, hereditary factor VIII deficiency, antihemophilic factor deficiency (AHF deficiency), Congenital factor VIII deficiency, Factor VIII:C deficiency |
| C. Adult onset | Likelihood of first onset in adulthood not low — in mild cases (FVIII 5–40%), which account for about 30–45% of the total, abnormal bleeding is often first recognized and diagnosed after age 18 in the absence of a clear trigger such as surgery, tooth extraction, or trauma; some moderate cases (FVIII 1–5%) may also first present in adulthood; severe cases (FVIII < 1%) are mostly diagnosed in infancy or childhood. |
| 1. History | Talmud (5th century) → Otto 1803 → Patek and Taylor 1937 FVIII discovery → Pool 1964 cryoprecipitate → 1984 F8 cloning → 1992 recombinant FVIII → 2017 emicizumab → 2022 gene therapy |
| 2. Causes | FVIII deficiency or reduced function due to pathogenic variants in the F8 gene (Xq28); X-linked recessive inheritance |
| 3. Genetics | F8 gene: 186 kb, 26 exons; intron 22 inversion (45–50% of severe cases), intron 1 inversion (5%), more than 2,000 pathogenic variants including point mutations, deletions, and insertions |
| 4. General epidemiology | 1 per 5,000–10,000 males; 80% of all hemophilia; about 2,400 registered in the Korean KBDR |
| 5. Pathophysiology | Loss of function of the intrinsic tenase complex (FIXa, FVIIIa, Ca²⁺, phospholipid) → insufficient FX activation → reduced thrombin generation → impaired fibrin clotting |
| 6. Symptoms | Severe: spontaneous hemarthrosis·muscle hematoma·intracranial hemorrhage; moderate: excessive bleeding after trauma; mild: delayed hemostasis after surgery·tooth extraction |
| 7. Signs | Isolated APTT prolongation, normal PT, normal platelets; decreased FVIII:C; corrected on mixing study; findings of hemarthropathy |
| 8. Screening | APTT prolongation → FVIII:C measurement → differentiation from vWF disorders → inhibitors → genetic testing |
| 9. Diagnosis | APTT → mixing → FVIII:C (one-stage and chromogenic assays) → differentiation from vWF disorders → Bethesda inhibitor assay → F8 genetic testing |
| 10. Treatment | DDAVP (mild), FVIII concentrates (SHL/EHL), emicizumab, fitusiran, gene therapy (valoctocogene roxaparvovec), inhibitor management (ITI/bypassing agents) |
| 11. Prognosis | With modern prophylaxis, life expectancy approaches normal; inhibitor development (25–30% of severe cases) is the key variable determining prognosis |
| 12. Prevention | Primary prophylaxis (started in infancy), genetic counseling, prenatal and preimplantation diagnosis, lifestyle adjustment |
| 13. References | WFH Guidelines for the Management of Haemophilia, 3rd ed. … and 9 other papers |
The history of hemophilia A begins with the written records of human history. The oldest record can be found in the Talmud (2nd–5th century AD), the scripture of Judaism. It states a rule that if two brothers died after circumcision, the next brother is exempted from circumcision, showing that even then it was empirically recognized that a bleeding tendency is inherited in males through the maternal line. The 10th-century Arab surgeon Al-Zahrawi (Abu al-Qasim Khalaf ibn Abbas Al-Zahrawi, Albucasis) also described men in certain families who experienced fatal bleeding after even minor trauma.
The modern medical description was made systematically in 1803 by John Conrad Otto of Philadelphia, USA. In his paper "An account of an hemorrhagic disposition existing in certain families," he clearly described the disease as being transmitted through mothers to sons. In 1828, Johann Lukas Schönlein of Germany first gave the disease the name "Hämophilie" (hemophilia), a term still used today.
In the first half of the 20th century, the biochemical basis of the disease began to be uncovered. In 1937, Patek and Taylor named the substance lacking in the plasma of hemophilia patients "antihemophilic factor (AHF)," and subsequent studies confirmed that this is coagulation factor VIII (FVIII). In 1952, Rosemary Biggs's research team described Christmas disease (hemophilia B), and hemophilia A and B were finally classified separately. From then on, hemophilia A also came to be called "classical" hemophilia.
One of the most important discoveries in the history of treatment was Judith Graham Pool's discovery of cryoprecipitate in 1964. Pool discovered that the material that precipitates when fresh frozen plasma (FFP) is thawed at 4°C contains high concentrations of FVIII, and cryoprecipitate therapy using it became a practical milestone in the treatment of hemophilia A. In the 1970s, plasma-derived FVIII concentrates were developed, advancing hemophilia treatment to the point where self-injection was possible, but this also led to the tragedy of large-scale harm caused by blood products contaminated with HIV and hepatitis C virus.
With advances in molecular medicine, Wood's research team succeeded in cloning the F8 gene in 1984, and in 1992 a recombinant FVIII product was first approved for clinical use, opening an era of treatment without infection risk. Since the 2000s, extended half-life (EHL) recombinant FVIII has been developed, greatly reducing dosing frequency. In 2017, emicizumab was approved after demonstrating outstanding prophylactic efficacy in the HAVEN 1 trial (in patients with inhibitors), and in 2019 its approved indication was expanded to patients without inhibitors. In 2022, the first AAV-based gene therapy (valoctocogene roxaparvovec) was approved in the EU for adults with severe hemophilia A, opening a new chapter in the history of hemophilia treatment aimed at a "functional cure."
Hemophilia A is an X-linked recessive genetic disease caused by deficiency or reduced function of coagulation factor VIII (FVIII) due to pathogenic variants in the F8 gene. The F8 gene is located at the distal end of the long arm of the X chromosome (Xq28), and variants in this gene result in reduced production, impaired secretion, or functional defects of the FVIII protein.
Under X-linked recessive inheritance, males (XY) with one X chromosome carrying the variant develop the disease, whereas females (XX, carriers) with one X chromosome carrying the variant mostly do not, because the F8 gene on the normal X chromosome compensates by producing enough FVIII. However, because of lyonization (random X-chromosome inactivation), carrier females in whom the normal X chromosome is predominantly inactivated can have markedly reduced FVIII activity and experience mild bleeding symptoms; they are called "symptomatic carriers."
De novo mutations are identified in about 30% of patients with hemophilia A. In these cases, the disease first appears without a family history, so it is difficult to predict in advance through prenatal screening or carrier testing. De novo mutations correspond to cases in which a new variant in the F8 gene arises during spermatogenesis or arises in the mother's germ cells.
Acquired FVIII deficiency is clinically similar to hemophilia A but arises by an entirely different mechanism; it corresponds to "acquired hemophilia A," in which autoantibodies (FVIII inhibitors) neutralize FVIII. It occurs mainly in older people, postpartum women, or patients with autoimmune diseases or malignancies, and must be managed separately from congenital hemophilia A.
The F8 gene is located at the distal end of the long arm of the X chromosome (Xq28) and, with a total length of about 186 kilobases (kb), is one of the largest genes in the human genome. It consists of 26 exons and is transcribed into an mRNA of more than 9,000 base pairs, which is then translated into a precursor protein of 2,351 amino acids (including the signal peptide). The mature FVIII protein has a domain structure of 6 domains, A1-A2-B-A3-C1-C2, and is stabilized in the blood by binding to von Willebrand factor (vWF).
The spectrum of gene variants causing hemophilia A is very broad. The most frequent and important variant is the intron 22 inversion, found in about 45–50% of patients with severe hemophilia A. In this mechanism, an inversion between a repeat sequence (A-region) located within intron 22 of the F8 gene and two homologous sequences on the distal X chromosome splits the F8 gene into two parts, making production of a functional protein impossible. The intron 1 inversion is another common large rearrangement, accounting for about 5% of severe cases.
Besides these two inversions, the remaining variants consist of various types, including point mutations (missense and nonsense variants), small deletions, small insertions, splicing variants, and large deletions and insertions. More than 2,000 pathogenic variants are currently registered in the HAMSTeRS (Hemophilia A Mutation, Structure, Test, and Resource Site) database. In general, variants that block protein production altogether (nonsense, large deletions, inversions, etc.) cause severe disease, while variants with partial effects on protein structure or function (missense, etc.) tend to be associated with mild or moderate disease.
The type of gene variant is closely associated with the risk of inhibitor development. Patients with large deletions, inversions, and nonsense variants have a markedly higher risk of inhibitor development than patients with mild missense variants. This is because the level of immune tolerance to endogenous FVIII protein differs by variant type. HLA genotype, polymorphisms in immune regulatory genes, and other factors also affect inhibitor development.
Hemophilia A is the most common severe congenital coagulation disorder, occurring worldwide in about 1 per 5,000–10,000 males. It accounts for about 80% of all hemophilia (types A + B), and according to the 2023 global report of the World Federation of Hemophilia (WFH), more than about 260,000 people worldwide are registered with hemophilia A. However, a substantial number of undiagnosed patients are thought to exist, especially in low- and middle-income countries.
By severity, severe cases (FVIII < 1%) account for about 40–50% of the total, moderate cases (FVIII 1–5%) about 10–15%, and mild cases (FVIII 5–40%) about 30–45%. It occurs with similar frequency in all races and ethnic groups, and geographic differences merely reflect differences in the spectrum of gene variants.
In Korea, according to the Korean Bleeding Disorder Registry (KBDR) and Health Insurance Review & Assessment Service (HIRA) data, there are about 2,300–2,500 registered patients with hemophilia A. In Korea as well, about 80% of all hemophilia patients have hemophilia A. After Special Copayment Reduction (V009) registration, a 10% copayment rate for related medical expenses applies for 5 years. Hemophilia treatment in Korea is provided within a support system of regional hub hospitals (comprehensive hemophilia treatment centers) and the Korea Hemophilia Foundation, and recombinant FVIII products and emicizumab are covered.
Because of X-linked inheritance, the overwhelming majority are male. Hemophilia A in females (FVIII activity below 40%) occurs in carrier females with X-chromosome inactivation skewed toward the pathogenic side, or in the very rare cases with F8 variants on both X chromosomes (homozygous or hemizygous). About half of female carriers have somewhat reduced FVIII:C, and some of them may experience bleeding complications during surgery or delivery.
The pathophysiology of hemophilia A stems from loss of the key cofactor role that FVIII plays in the coagulation cascade. In normal coagulation, when a blood vessel is injured, the extrinsic pathway (tissue factor-FVII complex) acts first to generate a small amount of thrombin. This small amount of thrombin triggers an amplification response that causes platelet activation, FVIII activation (FVIIIa), and FV activation (FVa).
Activated FVIIIa forms the intrinsic tenase complex together with FIXa and calcium ions on the phospholipid membrane surface. This complex amplifies the rate of activation of FX to FXa by tens of thousands of times or more compared with FIXa alone. FXa then converts prothrombin to thrombin, accelerating the amplification process that forms the fibrin clot.
In hemophilia A, FVIIIa itself is absent or functionally defective, so the intrinsic tenase complex does not form or its function is severely reduced. As a result, the rate of FX activation falls markedly, thrombin generation is insufficient, and a strong fibrin clot does not form. Because the primary hemostatic plug (platelet aggregation) forms normally, bleeding appears to stop readily from small wounds, but without secondary hemostatic reinforcement by fibrin, bleeding from large vessels or deep tissues cannot be adequately controlled.
Severity is determined by residual FVIII activity. In severe cases with FVIII activity below 1%, spontaneous bleeding (bleeding without external provocation) is frequent, and bleeding into joint spaces (hemarthrosis) in particular recurs. This is because TFPI (tissue factor pathway inhibitor), abundantly expressed by the synovial membrane, and the structural characteristics of the vessel wall limit hemostasis through the extrinsic pathway. Recurrent intra-articular bleeding leads to hemophilic arthropathy, progressing through synovial inflammation, iron-mediated oxidative damage, cartilage destruction, and bone erosion.
The symptoms of hemophilia A are closely linked to severity classification based on FVIII activity. An abnormal bleeding tendency is characteristic overall, but the pattern of presentation differs greatly by severity.
In severe disease (FVIII < 1%), spontaneous intra-articular bleeding (hemarthrosis) is the most common and characteristic symptom. The knees, ankles, and elbows are most often involved, followed by the hips, shoulders, and wrists. Early in hemarthrosis, a tingling prodrome in the joint is followed by rapid swelling, warmth, severe pain, and restricted movement. Muscle hematomas are also common, occurring frequently in the forearm, gastrocnemius, and iliopsoas. Iliopsoas hematoma in particular may be diagnosed late because signs of internal bleeding are not obvious, and it can cause leg paralysis and sensory disturbances from femoral nerve compression. Intracranial hemorrhage is the most serious complication of severe hemophilia and can cause death or permanent neurological damage. Most severe patients are diagnosed before their first birthday through prominent bruising or hemarthrosis.
In moderate disease (FVIII 1–5%), spontaneous bleeding is rare, but abnormally prolonged bleeding occurs even after minor trauma. Severe bleeding occurs after surgery or procedures, and joint bleeding also occurs but less frequently than in severe disease. Some patients are diagnosed in their teens or adulthood.
In mild disease (FVIII 5–40%), a bleeding tendency is rarely apparent in daily life. Abnormal bleeding is often first recognized at surgery, tooth extraction, delivery, or severe trauma. First diagnosis in adulthood is most frequent in this group. A typical scenario is diagnosis of hemophilia A after preoperative APTT prolongation is found.
The most specific bleeding patterns are joint, muscle, and soft tissue bleeding; deep hematomas and joint bleeding are more prominent than cutaneous petechiae or purpura (which suggest platelet dysfunction). Oral mucosal bleeding, epistaxis, hematuria, gastrointestinal bleeding, and others may also occur.
Signs of hemophilia A are divided into clinical examination findings and laboratory findings. Findings from both areas are combined to confirm the diagnosis and severity.
Clinical examination findings: With active hemarthrosis, marked swelling, warmth, skin tension, tenderness, and a marked reduction in range of motion of the joint are observed. When chronic hemophilic arthropathy has progressed, joint deformity (flexion contracture, angulation), periarticular muscle atrophy, and joint instability may occur. Muscle hematomas present as swelling, tenderness, induration, and local warmth over the affected muscle and may be accompanied by symptoms of compression of adjacent nerves. Skin bruises are common, but petechiae and purpura are rare (because platelet function is normal). In severe patients with a history of recurrent hemarthrosis, arthroscopy or MRI shows synovial thickening, iron deposition, and cartilage damage.
Laboratory findings: The most characteristic laboratory sign of hemophilia A is isolated prolongation of the APTT (activated partial thromboplastin time). The PT (prothrombin time) is normal, and the platelet count, fibrinogen, and thrombin time are all normal. Correction of the APTT on a mixing study (APTT remeasured after 1:1 mixing of patient plasma with normal plasma) suggests factor deficiency. When decreased FVIII:C (factor VIII coagulant activity) is confirmed, hemophilia A is strongly suspected. FVIII:C is measured by a one-stage clot-based assay or a chromogenic assay. When there is a significant discrepancy between the chromogenic and one-stage assays, suspect a patient using an EHL FVIII product or a specific F8 variant (such as B-domain deletion variants). Von Willebrand disease (vWD) type 2N is also accompanied by reduced FVIII:C, so vWF:Ag and vWF:RCo (ristocetin cofactor) must be measured together for differentiation.
Screening for hemophilia A is performed in the following contexts: (1) when it is clinically suspected because of a bleeding tendency or family history, (2) when APTT prolongation is incidentally found on routine coagulation testing before surgery or a procedure, (3) screening of carrier females or newborns with a family history.
The basic coagulation test panel consists of APTT, PT, platelet count, and fibrinogen. In hemophilia A, the typical pattern is prolonged APTT only, with the rest normal. For screening accuracy, the sensitivity to FVIII:C of the reagent used for APTT measurement is important; some reagents may report the APTT within the normal range in mild hemophilia (FVIII:C 5–40%), so when clinical suspicion is high, measuring FVIII:C directly is more accurate.
Direct measurement of FVIII:C is the most important test, serving for both screening and confirmation. Results are expressed as a percentage (%) of normal or in IU/dL: 40% or higher is normal, 5–40% mild, 1–5% moderate, and below 1% severe.
Confirming family history and carrier screening: The mother of a patient with hemophilia A is likely to be a carrier (except in de novo mutations), and when a family history is confirmed, FVIII:C measurement and F8 genetic testing are performed in female relatives to determine carrier status. Carrier females have FVIII:C reduced to an average of about 50%, but interindividual variation is large.
Newborn screening: When a family history is known, FVIII:C is measured in cord blood immediately after birth. In the neonatal period, FVIII:C is in the adult normal range, so measurement is possible (unlike FIX, it is not physiologically low). Prenatal diagnosis is performed by identifying the known familial F8 variant in fetal DNA obtained by chorionic villus sampling (11–14 weeks of gestation) or amniocentesis (15–18 weeks of gestation).
The diagnosis of hemophilia A is established through a stepwise testing algorithm. Starting from clinical suspicion, it proceeds through coagulation testing, factor activity measurement, differential diagnosis, and genetic confirmation, in that order.
Step 1: Basic coagulation tests. Isolated APTT prolongation is the first clue to hemophilia. Confirm that the PT, platelet count, and fibrinogen are normal.
Step 2: Mixing study. Patient plasma and normal plasma are mixed 1:1, and the APTT is remeasured immediately and after 2 hours of incubation at 37°C. Immediate correction suggests factor deficiency. If correction is insufficient, suspect an inhibitor or lupus anticoagulant.
Step 3: FVIII:C measurement. FVIII:C is measured by the one-stage clotting assay (aPTT-based) and the chromogenic assay to classify severity. If FVIII:C is reduced, the following differential diagnosis is needed.
Step 4: Differentiation from von Willebrand disease. In vWD type 2N (Normandy type), a variant in the FVIII-binding site of vWF reduces FVIII:C to 5–30%, which can be confused with hemophilia A. It is differentiated by vWF:Ag (vWF antigen), vWF:RCo (ristocetin cofactor activity), and the vWF:FVIII binding assay. vWD type 1 shows a mild decrease in vWF, and FVIII:C may also be reduced.
Step 5: Inhibitor testing. In previously treated patients or those whose treatment response is poorer than expected, the inhibitor titer is measured by the Bethesda assay or the Nijmegen-modified Bethesda assay. Below 0.6 BU/mL is classified as inhibitor negative, and 5 BU/mL or higher as a high-titer inhibitor.
Step 6: F8 genetic testing. Testing for the intron 22 inversion (inverse PCR or long-range PCR) is performed first; if negative, testing for the intron 1 inversion follows, then sequencing of the entire F8 gene (Sanger or NGS). Genetic test results are essential for predicting prognosis (inhibitor risk), identifying carriers in the family, and prenatal diagnosis.
Treatment of hemophilia A is broadly divided into treatment when bleeding occurs (on-demand therapy) and regular prophylaxis to prevent bleeding, and the modern standard of care is centered on prophylaxis.
Desmopressin (DDAVP): A synthetic vasopressin analog that releases endogenous stored FVIII and vWF in patients with mild hemophilia A (FVIII:C 5–40%). It is given intravenously (0.3 μg/kg) or as a high-concentration nasal spray and generally raises FVIII:C to 3–6 times the pretreatment baseline. It is effective for minor surgery, tooth extraction, and minor bleeding events. With repeated doses, the storage pool becomes depleted and the effect decreases (tachyphylaxis), and fluid retention and hyponatremia must be watched for. It is not used in moderate and severe patients or in patients with an insufficient response to DDAVP.
FVIII concentrates: There are two kinds, plasma-derived (pd-FVIII) and recombinant (rFVIII) products. Plasma-derived products that have undergone viral inactivation and recombinant products are currently regarded as equivalent in safety. Standard half-life (SHL) recombinant FVIII is given every 12 hours or, for hemophilia A prophylaxis, 2–3 times a week. Extended half-life (EHL) recombinant FVIII (e.g., efmoroctocog alfa-Fc, damoctocog alfa pegol) can be given 1–2 times a week, greatly improving the convenience of prophylaxis.
Emicizumab (Hemlibra): A bispecific monoclonal antibody that binds FIXa and FX simultaneously, functionally replacing the role of FVIIIa. It is given by subcutaneous injection and can be used regardless of the presence of FVIII inhibitors. Dosing options are once weekly, once every 2 weeks, or once every 4 weeks. The HAVEN 1 (adults with inhibitors), HAVEN 2 (children with inhibitors), HAVEN 3 (adults without inhibitors), and HAVEN 4 (dosing every 4 weeks) trials demonstrated reductions of 80–90% or more in the rate of hemarthrosis. Combining bypassing agent treatment (aPCC, FEIBA) during emicizumab use carries a risk of thrombosis and thrombotic microangiopathy, so the combination is in principle contraindicated.
Fitusiran: An siRNA-based subcutaneous injection that inhibits antithrombin (antithrombin III) synthesis in hepatocytes. When antithrombin decreases, thrombin generation is amplified and clotting capacity is enhanced. It can be used in both hemophilia A and B, regardless of the presence of inhibitors. Prophylaxis is maintained with a monthly subcutaneous injection. As of 2025 it is approved in the USA, the EU, Korea, and elsewhere.
Gene therapy: Valoctocogene roxaparvovec (Roctavian, AAV5-F8-SQ) is a gene therapy that uses an AAV5 vector to deliver a B-domain-deleted F8 gene to hepatocytes. It was first approved in the EU in 2022 for adults with severe hemophilia A. A single intravenous dose can sustain FVIII production for several years, potentially replacing weekly or biweekly injections. However, its efficacy may be limited in patients with preexisting AAV5 antibodies.
Inhibitor management: Inhibitors to FVIII products develop in about 25–30% of patients with severe hemophilia A. Bypassing agents (rFVIIa, aPCC) are used to treat bleeding in patients with inhibitors. In the long term, immune tolerance induction (ITI)—a method that eliminates the inhibitor by giving high-dose FVIII daily—is attempted. Emicizumab can be used as prophylaxis regardless of inhibitor status and has greatly changed the landscape of managing patients with inhibitors.
The prognosis of hemophilia A has improved dramatically over the past several decades with advances in treatment technology. Before the 1960s, life expectancy for patients with severe hemophilia was only 20–30 years, but in the era of recombinant FVIII prophylaxis, patients receiving appropriate prophylaxis have reached a life expectancy nearly equal to that of the general population. With the arrival of non-factor therapies such as emicizumab and fitusiran, the convenience and efficiency of prophylaxis are improving further.
Joint health is the most important factor for quality of life and long-term prognosis. Patients who started prophylaxis in infancy (at 18–24 months or before the first bleed) often maintain near-normal joints into adulthood. In contrast, patients who did not start prophylaxis in time or who continued to have recurrent hemarthrosis progress to chronic hemophilic arthropathy and may need treatment for chronic pain, loss of joint function, joint replacement, and so on.
Inhibitors are the most important complication determining the prognosis of hemophilia A. Neutralizing antibodies to FVIII products develop in about 25–30% of patients with severe hemophilia A, and when inhibitors are present, the effect of FVIII products is markedly reduced or lost. The risk of inhibitor development is determined by the type of F8 gene variant, the age and mode of first FVIII exposure, the immunogenetic profile, and other factors. If ITI succeeds after inhibitor development, the inhibitor can be eliminated, but the ITI success rate is about 70%, and switching to emicizumab to continue prophylaxis is also an effective strategy.
HIV and hepatitis C infections caused by contaminated blood products in the 1980s were a heavy burden for hemophilia patients at the time, but today this risk has effectively disappeared thanks to blood products with established viral safety, recombinant products, and the expansion of non-factor therapies. If gene therapy becomes widespread, the number of patients who can achieve a functional cure of hemophilia A is expected to increase further in the future.
Prevention in hemophilia A is broadly divided into three dimensions: prevention of bleeding itself (primary prophylaxis), prevention of complications, and genetic prevention.
Primary prophylaxis: The standard recommendation of the World Federation of Hemophilia (WFH) is to start regular FVIII (or emicizumab) administration before the first bleeding event or before age 2. Early prophylaxis is the most effective means of preventing hemarthrosis and stopping the progression of hemophilic arthropathy. The goal of FVIII prophylaxis is to keep FVIII:C at 1% or higher at all times (ideally 5% or higher). Emicizumab subcutaneous prophylaxis, given once weekly, once every 2 weeks, or once every 4 weeks, is far more convenient than conventional intravenous FVIII and has the advantage of being usable in patients with inhibitors.
Secondary and tertiary prophylaxis: Regular prophylaxis started after the first bleed (secondary prophylaxis) and prophylaxis to prevent further deterioration after arthropathy has already developed (tertiary prophylaxis) are also used. Whatever stage it starts at, prophylaxis markedly reduces bleeding frequency and the rate of joint damage.
Lifestyle adjustment: Avoiding vigorous contact sports (boxing, soccer, etc.) and activities with a high risk of falls is recommended. Low-impact aerobic exercise such as swimming, cycling, and walking is actually recommended because it helps strengthen muscles and control weight, protecting the joints. Aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), and antiplatelet agents impair platelet function and increase bleeding risk, so they are avoided. Intramuscular injections are avoided or minimized, and intravenous or subcutaneous routes are preferred.
Genetic counseling and prenatal diagnosis: Women identified as hemophilia A carriers should receive genetic counseling when planning a pregnancy and can determine the genetic status of the fetus through prenatal diagnosis (F8 gene analysis by CVS or amniocentesis) or preimplantation genetic testing (PGT-M). When a boy with confirmed hemophilia is to be delivered, plans are needed for the mode of delivery (no vacuum or forceps delivery, no scalp electrodes), management of the risk of intracranial hemorrhage immediately after birth, measurement of cord blood FVIII:C, and so on.
Inhibitor prevention: Studies suggest that the mode of initial FVIII exposure affects the risk of inhibitor development. Hypotheses have been raised that a first exposure as prophylaxis in the absence of bleeding and avoidance of intensive exposure in high-risk surgical settings may lower the risk of inhibitor development, but no established prevention guidelines exist yet.